Nitric oxide prevents Aft1 activation and metabolic remodeling in frataxindeficient yeast

dc.contributor.author
Alsina Obiols, David
dc.contributor.author
Ros Salvador, Joaquim
dc.contributor.author
Tamarit Sumalla, Jordi
dc.date.accessioned
2024-12-05T22:00:16Z
dc.date.available
2024-12-05T22:00:16Z
dc.date.issued
2018-03-13T11:44:20Z
dc.date.issued
2018-03-13T11:44:20Z
dc.date.issued
2018
dc.identifier
https://doi.org/10.1016/j.redox.2017.09.001
dc.identifier
2213-2317
dc.identifier
http://hdl.handle.net/10459.1/62826
dc.identifier.uri
http://hdl.handle.net/10459.1/62826
dc.description.abstract
Yeast frataxin homolog (Yfh1) is the orthologue of human frataxin, a mitochondrial protein whose deficiency causes Friedreich Ataxia. Yfh1 deficiency activates Aft1, a transcription factor governing iron homeostasis in yeast cells. Although the mechanisms causing this activation are not completely understood, it is assumed that it may be caused by iron-sulfur deficiency. However, several evidences indicate that activation of Aft1 occurs in the absence of iron-sulfur deficiency. Besides, Yfh1 deficiency also leads to metabolic remodeling (mainly consisting in a shift from respiratory to fermentative metabolism) and to induction of Yhb1, a nitric oxide (NO) detoxifying enzyme. In this work, we have used conditional Yfh1 mutant yeast strains to investigate the relationship between NO, Aft1 activation and metabolic remodeling. We have observed that NO prevents Aft1 activation caused by Yfh1 deficiency. This phenomenon is not observed when Aft1 is activated by iron scarcity or impaired iron-sulfur biogenesis. In addition, analyzing key metabolic proteins by a targeted proteomics approach, we have observed that NO prevents the metabolic remodeling caused by Yfh1 deficiency. We conclude that Aft1 activation in Yfh1-deficient yeasts is not caused by iron-sulfur deficiency or iron scarcity. Our hypothesis is that Yfh1 deficiency leads to the presence of anomalous iron species that can compromise iron bioavailability and activate a signaling cascade that results in Aft1 activation and metabolic remodeling.
dc.description.abstract
This work was supported by grants SAF2013-44820-R to J.R. (from Ministerio de Economia y Competitividad (Spain) and SGR2009-00196 from the Generalitat de Catalunya). We thank Roser Pané for technical assistance.
dc.language
eng
dc.publisher
Elsevier
dc.relation
info:eu-repo/grantAgreement/MINECO//SAF2013-44820-R/ES/MODELOS CELULARES DE ATAXIA DE FRIEDREICH: BASES MOLECULARES DE LA PATOLOGIA E IDENTIFICACION DE BIOMARCADORES Y COMPUESTOS CON POTENCIAL TERAPEUTICO/
dc.relation
Reproducció del document publicat a https://doi.org/10.1016/j.redox.2017.09.001
dc.relation
Redox Biology, 2018, vol. 14, p. 131-141
dc.rights
cc-by-nc-nd, (c) David Alsina et al., 2017
dc.rights
info:eu-repo/semantics/openAccess
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
Friedreich ataxia
dc.subject
Nitric oxide
dc.subject
Iron-sulfur
dc.subject
Metabolism
dc.subject
Targeted proteomics
dc.title
Nitric oxide prevents Aft1 activation and metabolic remodeling in frataxindeficient yeast
dc.type
article
dc.type
publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)